Healthy Skepticism Library item: 6730

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Follow-up: Boehringer Ingelheim’s promotion of Catovit (Prolintane)
MaLAM Australian News 1997 Jan-Feb; 5:(1-2):3

Abstract:

Boehringer-Ingelheim has responded to MaLAM’s earlier letter about the marketing of Catovit (prolintane) for “patients running on empty” and for “the post flu blues”. Although the company supplied MaLAM with 9 unpublished studies they do not show that the drug is effective.

Keywords:
*analysis/Australia/developing countries/Catovit/prolintane/Boehringer-Ingelheim/ appetite stimulants and suppressants/ children/ safety & risk information/ quality of information/MaLAM/Medical Lobby for Appropriate Marketing/ company responses/EVALUATION OF PROMOTION: DRUG SAFETY/EVALUATION OF PROMOTION: GENERAL QUALITY OF INFORMATION/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES